Immutep doses first patient in its TACTI─004 phase III clinical trial in first line non─small cell lung cancer
Immutep Limited, a late-stage immunotherapy company targeting cancer and autoimmune diseases, announced the first patient has been successfully dosed in its pivotal TACTI-004 phase III trial. TACTI-004 will evaluate Immutep’s eftilagimod alfa, a first-in- …